The US External Ventricular Drain market was valued at USD 134 Million in 2025 and is projected to reach USD 242 Million by 2035, registering a CAGR of 5.7% from 2024 to 2035. This report covers the competitive landscape, key market drivers, industry trends, regional market shares, and recent developments shaping the EVD market in the United States.
The economic impact of tariffs on "US External Ventricular Drain".
US External Ventricular Drain Market Growth Drivers
Increasing Prevalence of Neurological Disorders: The rising incidence of traumatic brain injuries, hydrocephalus, and intracranial hemorrhages in the US continues to drive demand for external ventricular drains. As per Codman Neuro (a Johnson & Johnson company), the frequency of acute neurological cases requiring immediate cerebrospinal fluid (CSF) management has grown by 6% per year, notably due to a higher aged population and improved diagnostic facilities. This surge necessitates advanced acute care neurosurgical devices, bolstering EVD adoption.
Advancements in EVD Technology: Companies such as Integra LifeSciences have introduced next-generation EVD systems featuring safer, minimally invasive catheters, enhanced anti-microbial materials, and integrated monitoring capabilities. These innovations reduce infection risk, improve patient outcomes, and simplify critical care for clinicians. The adoption of such advanced EVD systems, as reported by Integra in Q1 2024, has led to improved procedural efficiency in leading neurocritical care centers across the US.
US External Ventricular Drain Market Trends
Rising Adoption of Digital and Remote EVD Monitoring: 2024 has seen major hospitals pilot and implement smart, digitally monitored EVD systems capable of remote data transmission to clinicians, led by Medtronic's EVD digital integration platform. Remote and real-time intracranial pressure readings ensure improved patient safety, earlier intervention, and operational efficiency, reflecting the trend toward connected healthcare solutions.
Focus on Infection Control and Antimicrobial Innovation: The trend toward reducing EVD-related infections has driven the introduction of systems utilizing antimicrobial-impregnated catheters and closed systems. B. Braun Medical recently launched EVD kits incorporating advanced silver-based nano-coatings, aligning with US guidelines to limit nosocomial infections, and seeing notable adoption in academic medical centers in early 2024.
US External Ventricular Drain Market Opportunity
Emerging Use in Pediatric Neurology: Companies such as Medtronic are developing child-friendly EVD devices to address the rising cases of pediatric hydrocephalus, representing a significant opportunity in the US market.
Integrated EVD-Electronic Health Record Solutions: The future integration of EVD data streams into hospital EHRs, spearheaded by Philips, could streamline care team coordination and facilitate advanced outcome analytics, enhancing the market's value proposition.
US External Ventricular Drain Market Revenue (USD Million), 2020-2035
The chart illustrates a consistent growth trajectory of the US EVD market revenue from 2020 to 2035. In 2020, the market stood at USD 94 Million, with a steady rise each year, reflecting both increased procedure volumes and premium product adoption. By 2025, the market achieves USD 134 Million, and this upward trend continues, reaching USD 242 Million in 2035. Key growth phases are observed post-2024, attributed to technological advancement and expanded clinical indications. The sustained CAGR of 5.7% highlights the robust long-term potential for manufacturers and healthcare providers investing in this segment.
US External Ventricular Drain Market Share by Region (%) - 2025
The 2025 pie chart shows the dominance of the Northeast (28%) and West (25%) regions in the US EVD market, owed to larger hospital systems and advanced neurosurgical centers. The Midwest holds 20%, while the South captures 17%, reflecting growing but slightly lower procedural rates. The Southwest accounts for the remaining 10%. This distribution underlines regional disparities in neurocritical care infrastructure and accessibility, indicating market expansion opportunities, particularly in the South and Southwest as hospitals upgrade acute neurosurgical capabilities.
In April 2024, Integra LifeSciences announced the commercial release of their new Bactiguard®-coated EVD system in the US, aimed at minimizing catheter-associated infections. Early real-world data from two major trauma centers indicated a 30% reduction in infection incidence, positioning Integra strongly amid growing clinical demands for infection-protected neuro devices.
In March 2024, Medtronic launched a pilot of its digital EVD monitoring platform in collaboration with Mayo Clinic. Leveraging wireless data connectivity and artificial intelligence, the system enables ICU teams to remotely monitor and analyze cerebrospinal fluid drainage metrics, leading to faster response times and improved workflow efficiency.
In May 2024, B. Braun Medical received FDA clearance for its SilverShield™ EVD Catheter Kit, integrating advanced silver nanoparticle technology for antimicrobial protection. Following this, multiple academic hospitals commenced use of SilverShield™, reporting decreased EVD-related infections and highlighting a positive trend toward innovation-led patient safety enhancements across the US neurocritical care landscape.
Press Releases